• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2374-0124
    Volume 9, Issue 3
    Research Article
    Taysa Leite de Aquino, Jaiany Rodrigues Liborio, Ana Luiza Menezes Santana Bezerra, Giovana Macêdo Egidio Cavalcante, Dara Fernanda Brito Duarte, Ana Luiza de Aguiar Rocha Martin, Juliane dos Anjos de Paula, and Modesto Leite Rolim Neto*
    Introduction: Depression, being the most disabling disease in the world and presenting high morbidity and mortality, requires an effective treatment to ensure the maintenance of the patients' quality of life. About a third of patients do not respond adequately to antidepressant treatment. New pharmacological therapies are being approached in order to reduce the unfavorable outcomes resulting from this pathology.
    Objective: To develop a systematic review of the literature on the new possibilities of pharmacological treatments for depression in the last four years.
    Method: A systematic review was carried out following the PRISMA protocol (Preferred Reporting Items for Systematic Reviews and Meta-Analysis). We have included studies on the effectiveness of new pharmacological therapies in patients with major depressive disorder and treatment-resistant depression.
    Results: In the treatment of the major depressive disorder (MDD), the use of brexpiprazole 1 mg/day in addition to the usual antidepressant treatment (ADT), resulted in significant improvement in the main symptoms. Already referring to treatments for treatment-resistant depression (TRD): nasal esketamine proved beneficial in the short term, intravenous (IV), ketamine also appears as an effective therapy.
    Conclusion: The use of brexpiprazole 1 mg/day associated with an antidepressant, and the use of lactobacilli represent a new option for those with MDD. In addition, both ketamine, riluzole, and cariprazine appear as new hopes for those who have not yet achieved remission of the depressive disorder with the use of more than two antidepressants.
    Gudisa Bereda*
    Background: Pharmaceutical care is the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient’s quality of life. Worldwide, schizophrenia is associated with considerable disability and may affect educational and occupational performance.
    Objectives: To ascertain schizophrenia patients pharmaceutical care needs unmet and its associated factors in psychiatric ambulatory clinic of mettu karl referral hospital.
    Methods: An Institution based prospective cross sectional study design was carried out from May 07 /2021 to July 19/2021.Data was collected through employing check list and semi-structured questioner, and then the collected data was coded and analyzed by statistical packages for social sciences 25.0 version statistical software. Binary logistic regression analysis was used to identify factors associated with drug therapy problems. Finally, further analyses were carried out using multivariable analysis at a significance level of p-value <0.05.
    Findings: From the total 117 study subjects, 96(82.1%) of the respondents were ≥ 25 years. The overall incidence of drug therapy problem among schizophrenic patients in psychiatric ambulatory clinic follow up was 45(38.5%). Among seven types of drug therapy problem, 11(24.4%) of the study subjects were unnecessary drug therapy followed 9(20%), of participants had in-compliance. Rural residency (AOR=2.73,95%CI=2.162- 3.428,P=0.004), duration of schizophrenia treatment 6-10 years (AOR=2.73,95% CI=1.602- 2.850,P=0.014), frequency of attending follow up appointment in every 2 month (AOR=3.85,95%CI=2.790-6.20,P=0.037), patients who had comorbidities (AOR=2.17,95%CI=1.907-3.721, P=0.001), and patients who had taken haloperidol (AOR=2.69,95%CI=1.805-4.381,P=0.009), were associated factors of the outcome (DRPs).
    Conclusion and recommendation: Regarding duration of schizophrenia treatment majority of the participants taken the medication one year up to five years and had the frequency of attending follow up appointment every two months. Health care workers especially those who work at psychiatric where the patients about the medication usage and disease behaviors counsel.
  • JSciMed Central Blogs
  • JSciMed Central welcomes back astronaut Scott Kelly and cosmonaut Mikhail Kornienko.
    Readmore...

    Wonder Women Tech not only disrupted the traditional conference model but innovatively changed the way conferences should be held.
    Readmore...

    JSciMed Central Peer-reviewed Open Access Journals
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.